Biosimilars Market by Product (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application - Global Forecast to 2020.

Description: Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020.

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for cost-effective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, and are similar with regards to their quality, safety, and efficacy. The global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period.

This report studies and analyzes the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further segmented into insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormones; whereas, the recombinant glycosylated proteins market is further segmented into erythropoietin, monoclonal antibodies, and follitropin. The recombinant peptides market is segmented into calcitonin and glucagon. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant nonglycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant nonglycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin.

On the basis of applications, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and other applications (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure).

Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. The large share of the European region can be attributed to the rising budgetary pressures to reduce healthcare expenditure, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and government initiatives. On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder its market growth.

The global biosimilars market is highly competitive, with a large number of big and small market players. As of 2014, the global biosimilars market was dominated by Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel). Furthermore, new product launches and expansions are the major strategies adopted by major players to achieve growth in this market.

Reasons to Buy the Report:

From an insight perspective, this research report focused on various levels of analysis—industry analysis (industry trends and Porter’s five forces model), market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments in the biosimilars market; and high-growth regions/countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report
could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographies

- Product Development/Innovation: Detailed insights on research and development activities and new product launches in the biosimilars market

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various biosimilar products across geographies

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the biosimilars market

Contents:

1 Introduction
   1.1 Objectives Of The Study
   1.2 Market Definition
   1.3 Market Scope
      1.3.1 Market Segmentation
      1.3.2 Years Considered For The Study
   1.4 Currency
   1.5 Limitations
   1.6 Stakeholders

2 Research Methodology
   2.1 Market Size Estimation
   2.2 Market Breakdown And Data Triangulation
   2.3 Market Share Estimation
      2.3.1 Key Data From Secondary Sources
      2.3.2 Key Data From Primary Sources
      2.3.2.1 Key Industry Insights
      2.4 Assumptions For The Study

3 Executive Summary
   3.1 Introduction

4 Premium Insights
   4.1 Overall Biosimilars Market
   4.2 Biosimilars Market, By Type & Region
   4.3 Biosimilars Market, By Countries
   4.4 Recombinant Nonglycosylated Proteins Market, By Type
   4.5 Lifecycle Analysis, By Region

5 Market Overview
   5.1 Introduction
   5.2 Biosimilars Market Segmentation
      5.2.1 By Product
      5.2.2 By Application
      5.2.3 By Region
   5.3 Market Dynamics
      5.3.1 Drivers
         5.3.1.1 Growing Pressure To Curtail Healthcare Expenditure
         5.3.1.2 Increasing Demand For Biosimilar Drugs Due To Their Cost-Effectiveness
         5.3.1.3 Rising Incidences Of Diseases
5.3.1.4 Rise In Aging Population Triggers The Incidences Of Chronic Disorders
5.3.1.5 Strategic Collaborations Lead To Enhance Productivity And Clinical Trial Activities For Biosimilars
5.3.1.6 Increasing Government Support And Initiatives To Develop And Promote Biosimilars
5.3.2 Restraints
5.3.2.1 High Manufacturing Complexities And Costs
5.3.2.2 Innovative Strategies By Biologic Drug Manufacturers
5.3.3 Opportunities
5.3.3.1 Emerging Markets
5.3.3.2 Untapped Indications
5.3.3.3 Biologic Products Set To Be Off-Patent Will Offer Opportunities For Biosimilars
5.3.4 Challenges
5.3.4.1 Stringent Regulatory Requirements To Adversely Affect Investments In Biosimilars
5.3.5 Burning Issues
5.3.5.1 Product Withdrawals Provide Significant Opportunities For New Entrants

6 Industry Insights
6.1 Introduction
6.2 Porter’S Five Forces Analysis
6.2.1 Threat Of New Entrants
6.2.2 Threat Of Substitutes
6.2.3 Intensity Of Rivalry
6.2.4 Bargaining Power Of Suppliers
6.2.5 Bargaining Power Of Buyers
6.3 Key Pipeline Products
6.4 Regulatory Outlook
6.4.1 North America
6.4.1.1 U.S.
6.4.1.2 Canada
6.4.2 Europe
6.4.3 Asia-Pacific
6.4.3.1 China
6.4.3.2 India
6.4.3.3 Japan
6.4.3.4 South Korea
6.4.4 Rest Of The World
6.4.4.1 Brazil
6.4.4.2 Mexico
6.4.4.3 Argentina
6.4.4.4 Saudi Arabia
6.5 Biosimilars Services Industry Insights
6.5.1 Introduction
6.5.2 Contract Manufacturing Organizations
6.5.3 Contract Research Organizations
6.5.4 Other Services (Nonclinical & Bioinformatics)

7 Biosimilars Market, By Type Of Product
7.1 Introduction
7.2 Recombinant Non-Glycosylated Proteins
7.2.1 Insulin
7.2.2 Recombinant Human Growth Hormone (RHGH)
7.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
7.2.4 Interferons
7.3 Recombinant Glycosylated Proteins
7.3.1 Erythropoietin (Epo)
7.3.2 Monoclonal Antibodies (Mabs)
7.3.3 Follitropin
7.4 Recombinant Peptides
7.4.1 Glucagon
7.4.2 Calcitonin

8 Biosimilars Market, By Application
8.1 Introduction
8.2 Oncology
8.3 Blood Disorders
8.4 Chronic And Autoimmune Diseases
8.5 Growth Hormone Deficiency
8.6 Infectious Diseases
8.7 Other Applications

9 Biosimilars Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 U.K.
9.3.2 Germany
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest Of Europe
9.4 Asia-Pacific
9.4.1 China
9.4.2 India
9.4.3 Japan
9.4.4 South Korea
9.4.5 Rest Of Asia-Pacific (ROAP)
9.5 Rest Of The World (ROW)

10 Competitive Landscape
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation And Trends
10.3.1 New Product Launches And Regulatory Approvals
10.3.2 Agreements And Collaborations
10.3.3 Expansions
10.3.4 Acquisitions
10.3.5 Other Developments

11 Company Profiles
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 Introduction
11.2 Hospira, Inc.
11.3 Sandoz International GMBH (A Division Of Novartis International Ag)
11.4 Teva Pharmaceutical Industries Ltd.
11.5 Roche Diagnostics (A Division Of F. Hoffmann-La Roche Ltd.)
11.6 Amgen
11.7 Biocon Ltd.
11.8 Dr. Reddy’s Laboratories
11.9 Celltrion Inc.
11.10 Mylan Inc.
11.11 Merck Kgaa

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

12 Appendix
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Introducing Rt: Real-Time Market Intelligence
12.4 Available Customizations
12.5 Related Reports

List Of Tables

Table 1 Biosimilars Market: Major Collaborations (2012-2015)
Table 45 Biosimilars Market Size For Other Applications, By Region, 2012–2019 ($Million)
Table 46 Biosimilars Market Size, By Region, 2013–2020 ($Million)
Table 47 North America: Biosimilars Market Size, By Country, 2013–2020 ($Million)
Table 48 North America: Biosimilars Market Size, By Product, 2013–2020 ($Million)
Table 49 North America: Recombinant Nonglycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 50 North America: Recombinant Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 51 North America: Recombinant Peptides Market Size, By Type, 2013–2020 ($Million)
Table 52 North America: Biosimilars Market Size, By Application, 2013–2020 ($Million)
Table 53 U.S.: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 54 Canada: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 55 Europe: Biosimilars Market Size, By Product, 2013–2020 ($Million)
Table 56 Europe: Recombinant Nonglycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 57 Europe: Recombinant Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 58 Europe: Recombinant Peptides Market Size, By Type, 2013–2020 ($Million)
Table 59 Europe: Biosimilars Market Size, By Application, 2013–2020 ($Million)
Table 60 U.K.: Biosimilars Market Size, By Application, 2013–2020 ($Million)
Table 61 Germany: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 62 France: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 63 Spain: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 64 Italy: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 65 Roe: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 66 Asia-Pacific: Biosimilars Market Size, By Product, 2013–2020 ($Million)
Table 67 Asia-Pacific: Recombinant Nonglycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 68 Asia-Pacific: Recombinant Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 69 Asia-Pacific: Recombinant Peptides Market Size, By Type, 2013–2020 ($Million)
Table 70 Asia-Pacific: Biosimilars Market Size, By Application, 2013–2020 ($Million)
Table 71 China: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 72 India: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 73 Japan: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 74 South Korea: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 75 Roeapac: Biosimilars Market Size, By Type, 2013–2020 ($Million)
Table 76 Row: Biosimilars Market Size, By Product, 2013–2020 ($Million)
Table 77 Row: Recombinant Nonglycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 78 Row: Recombinant Glycosylated Proteins Market Size, By Type, 2013–2020 ($Million)
Table 79 Row: Recombinant Peptides Market Size, By Type, 2013–2020 ($Million)
Table 80 Row: Biosimilars Market Size, By Application, 2013–2020 ($Million)
Table 81 Recent New Product Launches And Regulatory Approvals, 2012–2015
Table 82 Recent Agreements And Collaborations, 2012–2015
Table 83 Recent Expansions, 2012–2015
Table 84 Recent Acquisitions 2012–2015
Table 85 Recent Other Developments, 2012–2015

List Of Figures

Figure 1 Global Biosimilars Market, By Product Type
Figure 2 Research Design
Figure 3 Top-Down Approach
Figure 4 Bottom-Up Approach
Figure 5 Breakdown Of Primary Interviews: By Company Type, Designation And Region
Figure 6 Data Triangulation Methodology
Figure 7 Market Snapshot: Recombinant Nonglycosylated Proteins To Dominate The Market
Figure 8 Asia-Pacific To Grow At The Highest Rate During The Forecast Period
Figure 9 Europe To Dominate Nonglycosylated Proteins Market During 2015-2020
Figure 10 Biosimilar Market: Geographic Snapshot
Figure 11 Biosimilars Market To Grow At A High Rate During The Forecast Period
Figure 12 Recombinant Nonglycosylated Proteins Segment Held The Largest Market Share In 2014
Figure 13 Germany Dominated The Biosimilars Market In 2014
Figure 14 Insulin Segment To Witness Highest Growth Rate From 2015 To 2020
Figure 15 Asia-Pacific To Witness High Growth In The Biosimilars Market During The Forecast Period
Figure 16 Biosimilars Market: Drivers, Restraints, Opportunities & Challenges
Figure 17 Global Biosimilars Market: Porter’s Five Forces Analysis
Figure 18 Insulin Is Expected To Grow At The Highest Cagr In The Forecast Period
Figure 19 Erythropoietin Is Expected To Dominate The Market In The Forecast Period
Figure 20 Glucagon Will Continue To Dominate The Market In The Forecast Period
Figure 21 Oncology Dominates The Biosimilars Applications Market
Figure 22 Geographic Snapshot (2015): Emerging Markets Hold Significant Growth Opportunities
Figure 23 Asia-Pacific, An Attractive Market For Biosimilars
Figure 24 North America: Market Snapshot
Figure 25 Recombinant Peptides Will Drive The Growth Of The Biosimilar Market In The U.S.
Figure 26 Recombinant Glycosylated Proteins Will Continue To Hold The Largest Share In The European Market
Figure 27 Asia-Pacific: Market Snapshot
Figure 28 Major Players Adopted The Strategy Of Approvals To Enhance Their Market Positions In The Biosimilars Market (2012-2015)
Figure 29 Global Biosimilars Market Share, By Key Player, 2014
Figure 30 Battle For Market Share: New Product Launches And Regulatory Approvals Was The Key Strategy Adopted By Market Players
Figure 31 Product Benchmarking For Top 3 Players
Figure 32 Hospira, Inc.: Company Snapshot
Figure 33 Sandoz International Gmbh: Company Snapshot
Figure 34 Teva Pharmaceutical Industries Ltd.: Company Snapshot
Figure 35 Roche Diagnostics: Company Snapshot
Figure 36 Amgen: Company Snapshot
Figure 37 Biocon Ltd.: Company Snapshot
Figure 38 Dr. Reddy's Laboratories: Company Snapshot
Figure 39 Celltrion Inc.: Company Snapshot
Figure 40 Mylan Inc.: Company Snapshot
Figure 41 Merck Kgaa: Company Snapshot

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3315099/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Biosimilars Market by Product (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application - Global Forecast to 2020.
Web Address: http://www.researchandmarkets.com/reports/3315099/
Office Code: SCH3XYF7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 5650</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 6650</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 8150</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World